Chronic Kidney Disease (CKD)EVACKDNCT07585695
Coronary Artery Disease Screening in Patients With Chronic Kidney Disease
An observational study of Chronic Kidney Disease (CKD) and Coronary Artery Disease (CAD), run by University Hospital, Grenoble at 1 site in France.
Trial summary
Patients with chronic kidney disease (CKD) have a markedly increased cardiovascular risk, with coronary artery disease being a leading cause of morbidity and mortality. Conventional cardiovascular risk scores and non-invasive diagnostic tests have limited accuracy in this population, partly due to atypical symptoms… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Kidney Disease (CKD), Coronary Artery Disease (CAD)
- How many people
- 283 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jun 2026to 31 Jan 2028
- How long will I take part?
- 25 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients from the University Hospital of Grenoble
Who may be able to join
- Male or female patients aged over 18 years
- Affiliated with the French social security system
- Patients at renal risk based on albuminuria (Alb) and glomerular filtration rate (GFR < 30 mL/min/1.73 m², or GFR < 45 mL/min/1.73 m² with albuminuria > 30 mg/g, or GFR < 60 mL/min/1.73 m² with albuminuria > 300 mg/g)
- Patients undergoing, independently of the research and according to the clinician's decision as part of standard care, CZT-SPECT myocardial perfusion imaging with coronary flow reserve measurement for cardiovascular risk assessment
- Having expressed no objection to participation in this study
Who cannot join
- Legally protected adult (Article L1121-8 of the French Public Health Code)
- Person deprived of liberty (Article L1121-8 of the French Public Health Code)
- Pregnant woman
- Patient who has undergone a normal coronary exploration within the past year
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
CHU Grenoble Alpes
La Tronche, France, 38700
Gilles Barone Rochette, PI, 0476765172, gbarone@chu-grenoble.fr
About this study
Official title: Screening for Coronary Artery Disease in Patients With Chronic Kidney Disease
Patients with chronic kidney disease (CKD) have a markedly increased cardiovascular risk, with coronary artery disease being a leading cause of morbidity and mortality. Conventional cardiovascular risk scores and non-invasive diagnostic tests have limited accuracy in this population, partly due to atypical symptoms and frequent structural heart disease. Coronary flow reserve (CFR) is a key marker of coronary microvascular dysfunction and has strong prognostic value, but its assessment is usually limited to invasive techniques. Recent advances in cadmium-zinc-telluride single-photon emission computed tomography (CZT-SPECT) allow non-invasive measurement of CFR. The EVACKD study aims to evaluate the prognostic value of CFR assessed by CZT-SPECT in patients with CKD for predicting major adverse cardiovascular events over a 2-year follow-up.
- Keywords
- Chronic Kidney Disease, Coronary Flow Reserve, coronary artery disease
- Medical subject headings
- Renal Insufficiency, Chronic, Coronary Artery Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess the prognostic value of impaired coronary flow reserve measured by CZT myocardial perfusion imaging
Composite endpoint including cardiac mortality, non-fatal myocardial infarction, non-fatal ischemic stroke, and hospitalization for heart failure.
Measured: 2-year follow-up
Secondary outcomes (5)
To assess the prognostic value of coronary flow reserve to each individual component of the primary endpoint
To evaluate each component separately : Cardiac mortality rate, non-fatal myocardial infarction rate, non-fatal ischemic stroke rate, hospitalization rate for heart failure, and all-cause mortality rate.
Measured: 2 years
To assess the prognostic value of coronary flow reserve for Major Adverse Kidney Events (MAKE)
Rate of patients with Major Adverse Kidney Events (MAKE), defined by the composite endpoint of death, dependence on renal replacement therapy, and a ≥50% decline in estimated glomerular filtration rate (eGFR) from baseline
Measured: At 1-year and 2-year follow-up
To assess the number of Acute Kidney Injury (AKI) events during follow-up
Evaluation of the Acute Kidney Injury (AKI) rate classified into three grades: Grade 1 (1.5- to 2-fold increase in serum creatinine), Grade 2 (2- to 3-fold increase), and Grade 3 (>3-fold increase or need for dialysis)
Measured: 2 years
To assess the number of coronary revascularizations by coronary artery bypass grafting or percutaneous coronary intervention
Performed by calculating the rate of revascularization by coronary artery bypass grafting or percutaneous coronary intervention
Measured: 2 years
To assess the prevalence of ischemic heart disease without significant coronary artery stenosis (INOCA)
Rate of ischemic heart disease without significant coronary artery stenosis (INOCA)
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2026
- Study start1 Jun 2026 (estimated)
- Primary completion30 Nov 2027 (estimated)
- Study completion31 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Kidney Disease (CKD)Studies of the same condition, open and under way.
- More trials run by University Hospital, GrenobleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 283 participants (estimated)
- Target duration
- 25 Months
Sponsor and investigators
- Lead sponsor
- University Hospital, Grenoble
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07585695
- Sponsor's protocol ID
- 38RC25.0302
- Other IDs
- IDRCB 2025-A02537-42, 38RC25.0302
- Acronym
- EVACKD
- Status last verified
- May 2026
- First submitted
- 6 May 2026
- Last updated
- 14 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Screening for Coronary Artery Disease in Patients With Chronic Kidney Disease
- ClinicalTrials.gov ID
- NCT07585695
- Acronym / sponsor ID
- EVACKD / 38RC25.0302
- Keywords
- Chronic Kidney Disease, Coronary Flow Reserve, coronary artery disease
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 283 participants (estimated)
- Lead sponsor
- University Hospital, GrenobleUniversity, hospital or other
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 30 Nov 2027 (estimated)
- Study completion
- 31 Jan 2028 (estimated)
- First posted
- 14 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with chronic kidney disease (CKD) have a markedly increased cardiovascular risk, with coronary artery disease being a leading cause of morbidity and mortality. Conventional cardiovascular risk scores and non-invasive diagnostic tests have limited accuracy in this population, partly due to atypical symptoms and frequent structural heart disease. Coronary flow reserve (CFR) is a key marker of coronary microvascular dysfunction and has strong prognostic value, but its assessment is usually limited to invasive techniques. Recent advances in cadmium-zinc-telluride single-photon emission computed tomography (CZT-SPECT) allow non-invasive measurement of CFR. The EVACKD study aims to evaluate the prognostic value of CFR assessed by CZT-SPECT in patients with CKD for predicting major adverse cardiovascular events over a 2-year follow-up.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 25 Months
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients from the University Hospital of Grenoble
Key inclusion criteria (5 listed)
- Male or female patients aged over 18 years
- Affiliated with the French social security system
- Patients at renal risk based on albuminuria (Alb) and glomerular filtration rate (GFR < 30 mL/min/1.73 m², or GFR < 45 mL/min/1.73 m² with albuminuria > 30 mg/g, or GFR < 60 mL/min/1.73 m² with albuminuria > 300 mg/g)
- Patients undergoing, independently of the research and according to the clinician's decision as part of standard care, CZT-SPECT myocardial perfusion imaging with coronary flow reserve measurement for cardiovascular risk assessment
- Having expressed no objection to participation in this study
Key exclusion criteria (4 listed)
- Legally protected adult (Article L1121-8 of the French Public Health Code)
- Person deprived of liberty (Article L1121-8 of the French Public Health Code)
- Pregnant woman
- Patient who has undergone a normal coronary exploration within the past year
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To assess the prognostic value of impaired coronary flow reserve measured by CZT myocardial perfusion imaging
Time frame: 2-year follow-up
Composite endpoint including cardiac mortality, non-fatal myocardial infarction, non-fatal ischemic stroke, and hospitalization for heart failure.
5 secondary outcomes
To assess the prognostic value of coronary flow reserve to each individual component of the primary endpoint
Time frame: 2 years
To assess the prognostic value of coronary flow reserve for Major Adverse Kidney Events (MAKE)
Time frame: At 1-year and 2-year follow-up
To assess the number of Acute Kidney Injury (AKI) events during follow-up
Time frame: 2 years
To assess the number of coronary revascularizations by coronary artery bypass grafting or percutaneous coronary intervention
Time frame: 2 years
To assess the prevalence of ischemic heart disease without significant coronary artery stenosis (INOCA)
Time frame: 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2026.
- Individual participant dataSharing planned: No
Related trials for Chronic Kidney Disease (CKD)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
An Individuation Intervention to Reduce Socioeconomic Disparities in Chronic Kidney Disease Care
Chronic Kidney Diseases
RecruitingPhase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Chronic Kidney Disease and Hypertension
RecruitingObservational study
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Recruiting
Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
Chronic Kidney Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Kidney Disease (CKD) and Coronary Artery Disease (CAD), run by University Hospital, Grenoble at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gilles Barone Rochette (+33476765172, gbarone@chu-grenoble.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess the prognostic value of impaired coronary flow reserve measured by CZT myocardial perfusion imaging (time frame: 2-year follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026.